Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.

Relative activity factors (RAFs) and immunoquantified levels of cytochrome P450 (CYP) isoforms both have been proposed as scaling factors for the prediction of hepatic drug metabolism from studies using cDNA-expressed CYPs. However, a systematic comparison of the two approaches, including possible mechanisms underlying differences, is not available. In this study, RAFs determined for CYPs 1A2, 2B6, 2C19, 2D6, and 3A4 in 12 human livers using lymphoblast-expressed enzymes were compared to immunoquantified protein levels. 2C19, 2D6, and 3A4 RAFs were similar to immunoquantified enzyme levels. In contrast, 1A2 RAFs were 5- to 20-fold higher than CYP1A2 content, and the RAF:content ratio was positively correlated with the molar ratio of NADPH:CYP oxidoreductase (OR) to CYP1A2. The OR:CYP1A2 ratio in lymphoblast microsomes was 92-fold lower than in human liver microsomes. Reconstitution experiments demonstrated a 10- to 20-fold lower activity at OR:CYP1A2 ratios similar to those in lymphoblasts, compared with those in human livers. CYP2B6-containing lymphoblast microsomes had 29- and 13-fold lower OR:CYP and cytochrome b(5):CYP ratios, respectively, than did liver microsomes and yielded RAFs that were 6-fold higher than CYP2B6 content. Use of metabolic rates from cDNA-expressed CYPs containing nonphysiologic concentrations of electron-transfer proteins (relative to human liver microsomes) in conjunction with hepatic CYP contents may lead to incorrect predictions of liver microsomal rates and relative contributions of individual isoforms. Scaling factors used in bridging the gap between expression systems and liver microsomes should not only incorporate relative hepatic abundance of individual CYPs but also account for differences in activity per unit enzyme in the two systems.

[1]  D J Greenblatt,et al.  Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. , 1999, Biochemical pharmacology.

[2]  D. Greenblatt,et al.  Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. , 1993, Pharmacology.

[3]  H. Yamazaki,et al.  Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[4]  C. Crespi.  Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[5]  A. Parkinson,et al.  Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. , 1996, Archives of biochemistry and biophysics.

[6]  D. Greenblatt,et al.  Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. , 2000, The Journal of pharmacology and experimental therapeutics.

[7]  D. Greenblatt,et al.  CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[8]  D. Waxman,et al.  Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[9]  D. Greenblatt,et al.  Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine , 1996, Psychopharmacology.

[10]  R. Estabrook,et al.  The measurement of difference spectra: application to the cytochromes of microsomes. , 1978, Methods in enzymology.

[11]  J S Harmatz,et al.  Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.

[12]  D. Greenblatt,et al.  Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. , 1998, Journal of pharmaceutical sciences.

[13]  D. Greenblatt,et al.  Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. , 1998, Journal of pharmaceutical sciences.

[14]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[15]  B. W. Penman,et al.  Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. , 1997, Advances in pharmacology.

[16]  D. Greenblatt,et al.  Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.

[17]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[18]  A. H. Phillips,et al.  Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. , 1962, The Journal of biological chemistry.

[19]  D. Waxman,et al.  Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[20]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[21]  Kaoru Kobayashi,et al.  Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[22]  S. Rotzinger,et al.  Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[23]  P M Shaw,et al.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  H. Yamazaki,et al.  Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[25]  B. Burchell,et al.  Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. , 1993, Biochemical pharmacology.

[26]  D. Greenblatt,et al.  Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects , 1999, Biological Psychiatry.

[27]  H. Greim,et al.  Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[28]  D. Greenblatt,et al.  In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors , 2000, Biological Psychiatry.

[29]  M. Wester,et al.  Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. , 1998, Archives of biochemistry and biophysics.

[30]  D. Waxman,et al.  Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. , 2000, Biochemical pharmacology.

[31]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[32]  H. Yamazaki,et al.  Cytochrome P450 reconstitution systems. , 1998, Methods in molecular biology.

[33]  Karthik Venkatakrishnan,et al.  Nortriptyline E‐10‐Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme‐Inducing Drugs , 1999, Journal of clinical pharmacology.

[34]  D. Stresser,et al.  Monospecific antipeptide antibody to cytochrome P-450 2B6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[35]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[36]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[37]  J S Harmatz,et al.  Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.